Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QTc prolongation with antidepressants in adults with anxiety disorders
NL-OMON38604Phase 4Active, not recruiting
- Sponsor
- Parnassia Therapeutics
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of antidepressant (TDDS/ODF) in anxiety disorder (4 arms), sponsored by Parnassia Therapeutics. Primary endpoint: Incidence of QTc prolongation. Started Jul 2014; status: active, not recruiting.
02
Drugs
antidepressant (TDDS/ODF)
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on NL-OMON38604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38604.